NYSE$RCUS
Arcus Biosciences Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Arcus Biosciences reported its fourth-quarter and full-year 2024 financial results, highlighting pipeline advancements and a strong cash position.
Arcus Biosciences reported a net loss of $94 million for Q4 2024, an increase from $81 million in Q4 2023, despite an increase in total revenues to $36 million. The company ended the year with a strong cash position of $992 million, positioning it well for upcoming pivotal readouts.
- New data from the Phase 1/1b ARC-20 study showed that casdatifan improved upon the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date.
- Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan in combination with cabozantinib versus cabozantinib in IO-experienced patients with clear cell renal cell carcinoma (ccRCC) is expected in the first half of 2025.
- Arcus completed a $150 million financing and continues to be well positioned to advance its pipeline with $992 million in cash, cash equivalents and marketable securities as of December 31, 2024.
- The company expects its cash and investments, together with proceeds from the February 2025 equity financing, to provide funding through initial pivotal read-outs for domvanalimab, quemliclustat and casdatifan.
Headline financials
Revenue & EPS history
Arcus Biosciences · Revenue · Quarterly
$36M
Revenue by segment
Arcus Biosciences · $10M total across 1 segment · Q3 2023
- Other collaboration$10M+1.6%100.0%
Forward guidance
Arcus Biosciences anticipates advancing its pipeline with a strong cash position, initiating new clinical trials, and expecting key data readouts in 2025 and 2026.
Tailwinds
- Initiation of the Phase 3 PEAK-1 study for casdatifan in IO-experienced ccRCC is expected in the first half of 2025.
- Initial data from the ARC-20 cohort evaluating casdatifan plus cabozantinib are expected to be presented in mid-2025.
- Three new expansion cohorts within ARC-20 will be initiated in the first quarter of 2025, including casdatifan plus zimberelimab in all-comer 1L ccRCC.
- Overall survival data from the Phase 2 EDGE-Gastric study for domvanalimab plus zimberelimab and chemotherapy are expected in fall 2025.
- Arcus anticipates advancing AB801 into expansion cohorts in non-small cell lung cancer (NSCLC) in the second half of 2025.
Headwinds
- Preliminary and interim data are not guarantees that future data will be similar.
- Unexpected emergence of adverse events or other undesirable side effects in investigational products could occur.
- Difficulties or delays in initiating or conducting clinical trials due to regulatory process, enrolling subjects, or manufacturing/supply issues.
- Unfavorable global economic, political, and trade conditions could impact operations.
- Inherent uncertainty associated with pharmaceutical product development and clinical trials.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+2.4%
Avg return
Earnings day
+3.6%
Avg return
5 days after
+6.7%
Avg return
30 days after
59%
19 / 32 earnings
Positive
+19.2%
Q4 2021
Best reaction
-7.9%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -2.6% | -5.6% | |
| Q4 2025 | -4.0% | +10.7% | +0.0% | |
| Q3 2025 | -1.1% | +2.7% | +28.9% | |
| Q1 2025 | -1.2% | +8.4% | +22.8% | |
| Q4 2024 | -1.0% | -7.3% | -18.4% | |
| Q3 2024 | +7.7% | +16.1% | +13.1% | |
| Q2 2024 | +11.5% | +11.7% | +12.3% | |
| Q1 2024 | +3.8% | +10.6% | -0.4% | |
| Q4 2023 | +18.5% | +18.4% | -1.0% | |
| Q3 2023 | +2.8% | -13.0% | +0.4% | |
| Q2 2023 | -3.0% | -4.3% | +18.3% | |
| Q1 2023 | -5.2% | -6.9% | +9.0% | |
| Q4 2022 | -4.0% | +0.6% | -3.7% | |
| Q3 2022 | -2.2% | -7.9% | +43.2% | |
| Q2 2022 | +6.0% | +7.9% | -2.1% | |
| Q1 2022 | +11.9% | -9.7% | +10.1% | |
| Q4 2021 | +19.2% | +24.6% | +20.4% | |
| Q3 2021 | +11.4% | +9.1% | +26.5% | |
| Q2 2021 | -7.3% | -2.5% | +13.7% | |
| Q1 2021 | -7.9% | -11.7% | -23.4% | |
| Q4 2020 | +2.9% | +10.3% | -1.7% | |
| Q3 2020 | -7.1% | +3.8% | +33.1% | |
| Q2 2020 | +2.3% | +8.1% | -1.1% | |
| Q1 2020 | -0.7% | +11.4% | +11.3% | |
| Q4 2019 | +7.1% | -2.6% | -19.8% | |
| Q3 2019 | +1.6% | -6.3% | -3.2% | |
| Q2 2019 | +1.8% | +10.3% | +18.2% | |
| Q1 2019 | +4.9% | +9.1% | -15.5% | |
| Q4 2018 | -6.8% | +11.6% | -3.7% | |
| Q3 2018 | +8.9% | -1.1% | +8.0% | |
| Q2 2018 | +2.2% | +7.5% | +19.0% | |
| Q1 2018 | +2.9% | -1.1% | +6.9% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro